ATEM Capital

ATEM Capital manages evergreen Life Sciences investment fund - Health Square Fund (HSF). HSF acts as a consolidator of capital flows from the Emerging Markets and invests into the biotech innovation hubs of the US/Western Europe. HSF's international team combines big-picture business perspective with decades of investment scientific legal portfolio risk management and operational experience. The fund is audited by a Big-4 firm. Our Advisory Board comprises high-caliber entrepreneurs VC veterans and seasoned Wall Street professionals.
Alexey Afanasiev
Executive Partner 
Anton Gopka
CEO General Partner 
Elena Ikhsanova
COO General Partner 

Baxter Ventures

Baxter Ventures is the strategic venture arm of Baxter International Inc. that was formed in 2011 and is based in Deerfield, Illinois. The firm is currently making equity investments out of a $200 Million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

Priyanka Rohatgi
Director 

BioScience Managers Australia

BioScience Managers is a venture capital life science investment firm headquartered in Melbourne, Australia. The group makes equity investments from $3M-5M and anticipates about 6 new investments this year. BioScience Managers invests globally. 

BioScience Managers will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. BioScience Managers considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. BioScience Managers seeks investments in novel technology and is not looking to gain share of an existing market. 

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Jeremy Curnock Cook
Managing Director 
Amanda Gillon
Investment Analyst 
Matt McNamara
CIO 

Biosight, LLC and MIT United States

Biosight, LLC  is a start-up biomedical device company developing a low-cost technology that will enable health care providers (HCPs) to discriminate amongst different types of tissues so that they will no longer need to use the blind and semi-blind approach to procedural instrument placement. The key intellectual capital of Biosight, LLC, (Biosight) is medical procedure needle tip tissue identification using multimodal spectroscopy (MMS) technologies first developed in the Laser Biomedical Research Center (LBRC) at the Massachusetts Institute of Technology. Several founding members of Biosight are the pioneers in this field and have established collaborations with clinicians at the Massachusetts General Hospital to identify clinical areas for this technology. Currently, Biosight, LLC is working with several investors in Massachusetts to further develop the device for numerous clinical applications

Year Founded
2014
Main Sector
Biotech Subsector
Biotech Phase of Development
Medtech Phase of Development
Alliance & Collaborations
Massachusetts Institute of Technology and Massachusetts General Hospital
Current Financing Needs
$10M
IP Status
Application Filed
Recent Milestones
Finalist in MIT 100K Pitch 2014
Management Team Highlights
Harvard and MIT Collaborators
Cheryl Campbell
Cheryl Campbell
LinkedIn logo MIT MBA Student and Intellectual Property Attorney 
BIO

A cancer scientist, corporate/IP lawyer and MBA candidate at the MIT Sloan School of Management who is dedicated to commercializing innovative biopharmaceutical products and medical devices that benefit patients. I have acquired diverse experience in the health care and life sciences industries spanning discovery, commercialization and regulatory development. My goal is to create and execute business and legal strategies that successfully drive products to market and create overall value for patient care. Capabilities include research design, assay development, clinical trial management, market/financial analysis, data modeling, operational design and management, system dynamics, drafting regulations, stakeholder engagement, intellectual property, licensing and contract drafting/negotiations.

Breakout Labs

Breakout Labs was founded by the Thiel Foundation in 211 and is based in San Francisco CA. Breakout Labs provides seed grants of $35 to 8-1 early stage companies per year. Companies must reach specific milestones in order to receive installments of the grant. Breakout Labs grants are in the form of a convertible note that if the company raises a Series A round will convert based on the Series A valuation, however if the company fails before raising a Series A round no debt will be due. Additionally when a portfolio company becomes revenue-generating or is acquired Breakout Labs receives a 3% royalty payment capped at 3x the value of the grant. Breakout Labs funds companies throughout the USA.
Lindy Fishburne
Executive Director 
Michelle Kim-Danely
Portfolio Manager 

Broadview Ventures

Broadview Ventures is a Philanthropy Venture firm that was established by the Leducq Family Trust in 28 and dedicated to accelerating the translation of new and innovative programs in the CV and stroke areas. The firm is based out of Boston MA but is geographically agnostic in its investing. The firm makes equity and convertible note investments of approximately $1 million into companies that are targeting cardiovascular and neurovascular diseases. The firm invests in privately held companies at both the seed and venture stage and is currently invests in 4-5 companies per year. The firm operates under an evergreen structure and is constantly seeking new investment opportunities. While the firm will consider investments around the globe Broadview is keen to add companies based in Europe to its portfolio. Broadview has previously invested in the US Europe and Israel.
Maria Berkman
Director 
Rick Jones
Director 
Christopher de Souza
Director 

Chempetitive Group

Chempetitive Group is an integrated marketing communications agency focused exclusively on the life sciences. We work with biotech, medical device, pharmaceutical, chemical and tools/instrumentation companies of all sizes that around the globe. We develop winning strategies and campaigns that build brands and generate revenues. We love science. We understand science. And, we know how to effectively reach the scientific, clinical, medical and business communities that matter. 

Long live science. 

Visit us in San Diego, San Francisco, Chicago, Boston or Cambridge UK. 

Find out about us at http://www.chempetitive.com 

Erik Clausen
Erik Clausen
LinkedIn logo Managing Partner 
BIO

Erik Clausen is a managing partner at Chempetitive Group (http://www.chempetitive.com), a marketing communications firm that develops and implements strategies and drives results for life science and healthcare companies. Erik brings two decades of international experience helping life science, medical technology and healthcare organizations to reach and engage the right audiences.

Chiesi Ventures

Chiesi Ventures is a Venture Capital firm formed by a partnership between the Italian Pharmaceutical company Chiesi and US based VC firm Pappas Ventures. The firm is currently looking to make seed and venture stage investments into companies ranging anywhere from $2K to $5 million initially and up to $8 million over the life of the investment. The firm is actively seeking investment opportunities throughout the United States and Europe and could make as many as 2-4 new investments over the next year.
Art Pappas
Partner 

CitareTx Investment Partners

CitareTx founded in 2008 is a venture development and investment firm based in Houston Texas. The firm provides investment and incubation services to start-up and early-stage medical device companies. The firm provides seed capital (equity) ranging from $5K to $2M with follow-on capital of up to $5M. The firm also considers investment opportunities with smaller than typically accepted venture capital market size thresholds. The firm is geographically agnostic but prefers companies to be based in Texas. The firm is actively seeking new opportunities.

Jeffery Sheldon
General Partner & Managing Director